|
ERCC8 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62503344114384E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.88178419700125E-16 |
| Normal-vs-Stage2 |
1.055480E-03 |
| Normal-vs-Stage3 |
4.36539693282612E-13 |
| Normal-vs-Stage4 |
1.62481139653892E-12 |
| Stage1-vs-Stage2 |
1.518850E-03 |
| Stage1-vs-Stage3 |
2.332200E-01 |
| Stage1-vs-Stage4 |
3.263600E-03 |
| Stage2-vs-Stage3 |
1.116940E-03 |
| Stage2-vs-Stage4 |
1.69560999999652E-05 |
| Stage3-vs-Stage4 |
6.302300E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.33066907387547E-16 |
| Normal-vs-AfricanAmerican |
4.0333000000059E-05 |
| Normal-vs-Asian |
2.52809995160419E-11 |
| Caucasian-vs-AfricanAmerican |
3.287200E-01 |
| Caucasian-vs-Asian |
8.833400E-01 |
| AfricanAmerican-vs-Asian |
4.133600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.43419720544102E-11 |
| Normal-vs-Female |
1.62470037423645E-12 |
| Male-vs-Female |
9.660200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62481139653892E-12 |
| Normal-vs-Age(41-60Yrs) |
1.97064586870965E-13 |
| Normal-vs-Age(61-80Yrs) |
5.94019999855533E-09 |
| Normal-vs-Age(81-100Yrs) |
1.880860E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.935800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.488170E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.905600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.928020E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.618200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.609800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.282600E-03 |
| Classical-VS-Follicular |
3.60780000000505E-05 |
| Classical-VS-Other |
6.256200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
8.63969999986836E-08 |
| Tall-VS-Other |
4.089400E-01 |
| Tall-VS-Normal |
1.19904086659517E-14 |
| Follicular-VS-Other |
8.043600E-02 |
| Follicular-VS-Normal |
3.637700E-04 |
| Other-VS-Normal |
2.046000E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.66829941159608E-11 |
| Normal-vs-N1 |
9.99200722162641E-16 |
| N0-vs-N1 |
3.227600E-04 |
|
|
